Hepatic iron overload and risk of hepatocellular carcinoma in cirrhosis

Gastroenterologie Clinique et Biologique

Volumn 34, Issue 1, 2010, Pages 1-7

  Nahon, P ^a   Ganne Carrie N ^a   Trinchet, J C ^a   Beaugrand, M ^a  

^a HÔPITAL JEAN VERDIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HFE PROTEIN;

ALCOHOL LIVER DISEASE; CANCER RISK; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG RESPONSE; GENE MUTATION; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IRON OVERLOAD; LIPID PEROXIDATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LONGITUDINAL STUDY; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON OVERLOAD; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MUTATION; RISK; RISK FACTORS;

EID: 74149093481     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.07.032     Document Type: Short Survey

References (68)

1. Deugnier Y., and Turlin B. Pathology of hepatic iron overload. World J Gastroenterol 13 (2007) 4755-4760
2. Deugnier Y. Iron and liver cancer. Alcohol 30 (2003) 145-150
3. Elmberg M., Hultcrantz R., Ekbom A., Brandt L., Olsson S., Olsson R., et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 125 (2003) 1733-1741
4. Blanc J.F., de Ledinghen V., Bernard P.H., de Verneuil H., Winnock M., Le Bail B., et al. Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in noncirrhotic liver. J Hepatol 32 (2000) 805-811
5. Bralet M.P., Regimbeau J.M., Pineau P., Dubois S., Loas G., Degos F., et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 32 (2000) 200-204
6. Turlin B., Juguet F., Moirand R., Le Quilleuc D., Loreal O., Campion J.P., et al. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 22 (1995) 446-450
7. Kowdley K.V. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127 Suppl. 1 (2004) S79-86
8. Ganne-Carrie N., Christidis C., Chastang C., Ziol M., Chapel F., Imbert-Bismut F., et al. Liver iron is predictive of death in alcoholic cirrhosis: a multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a prospective follow-up study. Gut 46 (2000) 277-282
9. Gandon Y., Olivie D., Guyader D., Aube C., Oberti F., Sebille V., et al. Noninvasive assessment of hepatic iron stores by MRI. Lancet 363 (2004) 357-362
10. Duane P., Raja K.B., Simpson R.J., and Peters T.J. Intestinal iron absorption in chronic alcoholics. Alcohol Alcohol 27 (1992) 539-544
11. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
12. Tsukamoto H., Lin M., Ohata M., Giulivi C., French S.W., and Brittenham G. Iron primes hepatic macrophages for NF-kappaB activation in alcoholic liver injury. Am J Physiol 277 (1999) G1240-G1250
13. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113 (2004) 1271-1276
14. Suzuki M, Fujimoto Y, Suzuki Y, Hosoki Y, Saito H, Nakayama K, et al. Induction of transferrin receptor by ethanol in rat primary hepatocyte culture. Alcohol Clin Exp Res 2004;28(Suppl. 8):98S-105S.
15. Harrison-Findik D.D. Role of alcohol in the regulation of iron metabolism. World J Gastroenterol 13 (2007) 4925-4930
16. Ioannou G.N., Dominitz J.A., Weiss N.S., Heagerty P.J., and Kowdley K.V. The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. Gastroenterology 126 (2004) 1293-1301
17. Raynard B., Balian A., Fallik D., Capron F., Bedossa P., Chaput J.C., et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 35 (2002) 635-638
18. Adams P.C., and Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Hepatology 23 (1996) 724-727
19. Frenzer A., Rudzki Z., Norton I.D., Butler W.J., and Roberts-Thomson I.C. Heterozygosity of the haemochromatosis mutation, C282Y, does not influence susceptibility to alcoholic cirrhosis. Scand J Gastroenterol 33 (1998) 1324
20. Gleeson D., Evans S., Bradley M., Jones J., Peck R.J., Dube A., et al. HFE genotypes in decompensated alcoholic liver disease: phenotypic expression and comparison with heavy drinking and with normal controls. Am J Gastroenterol 101 (2006) 304-310
21. Grove J., Daly A.K., Burt A.D., Guzail M., James O.F., Bassendine M.F., et al. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut 43 (1998) 262-266
22. Lauret E., Rodriguez M., Gonzalez S., Linares A., Lopez-Vazquez A., Martinez-Borra J., et al. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol 97 (2002) 1016-1021
23. Nahon P., Charnaux N., Friand V., Prost-Squarcioni C., Ziol M., Lievre N., et al. The manganese superoxide dismutase Ala16Val dimorphism modulates iron accumulation in human hepatoma cells. Free Radic Biol Med 45 (2008) 1308-1317
24. Sutton A., Nahon P., Pessayre D., Rufat P., Poire A., Ziol M., et al. Genetic polymorphisms in antioxidant enzymes modulate hepatic iron accumulation and hepatocellular carcinoma development in patients with alcohol-induced cirrhosis. Cancer Res 66 (2006) 2844-2852
25. Martinelli A.L., Filho A.B., Franco R.F., Tavella M.H., Ramalho L.N., Zucoloto S., et al. Liver iron deposits in hepatitis B patients: association with severity of liver disease but not with hemochromatosis gene mutations. J Gastroenterol Hepatol 19 (2004) 1036-1041
26. Bonkovsky H.L., Naishadham D., Lambrecht R.W., Chung R.T., Hoefs J.C., Nash S.R., et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 131 (2006) 1440-1451
27. Distante S., Bjoro K., Hellum K.B., Myrvang B., Berg J.P., Skaug K., et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 22 (2002) 269-275
28. Lebray P., Zylberberg H., Hue S., Poulet B., Carnot F., Martin S., et al. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. J Viral Hepat 11 (2004) 175-182
29. Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 124 (2003) 1509-1523
30. Sebastiani G., Vario A., Ferrari A., Pistis R., Noventa F., and Alberti A. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. J Viral Hepat 13 (2006) 199-205
31. Aoki C.A., Rossaro L., Ramsamooj R., Brandhagen D., Burritt M.F., and Bowlus C.L. Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. J Clin Gastroenterol 39 (2005) 71-74
32. Corengia C., Galimberti S., Bovo G., Vergani A., Arosio C., Mariani R., et al. Iron accumulation in chronic hepatitis C: relation of hepatic iron distribution, HFE genotype, and disease course. Am J Clin Pathol 124 (2005) 846-853
33. Erhardt A., Maschner-Olberg A., Mellenthin C., Kappert G., Adams O., Donner A., et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 38 (2003) 335-342
34. Kazemi-Shirazi L., Datz C., Maier-Dobersberger T., Kaserer K., Hackl F., Polli C., et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 116 (1999) 127-134
35. Negro F., Samii K., Rubbia-Brandt L., Quadri R., Male P.J., Zarski J.P., et al. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J Med Virol 60 (2000) 21-27
36. Smith B.C., Gorve J., Guzail M.A., Day C.P., Daly A.K., Burt A.D., et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 27 (1998) 1695-1699
37. Thorburn D., Curry G., Spooner R., Spence E., Oien K., Halls D., et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 50 (2002) 248-252
38. Tung B.Y., Emond M.J., Bronner M.P., Raaka S.D., Cotler S.J., and Kowdley K.V. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 124 (2003) 318-326
39. Senba M., Nakamura T., and Itakura H. Statistical analysis of relationship between iron accumulation and hepatitis B surface antigen. Am J Clin Pathol 84 (1985) 340-342
40. Fargion S., Mattioli M., Fracanzani A.L., Sampietro M., Tavazzi D., Fociani P., et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 96 (2001) 2448-2455
41. Day C.P., and James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 114 (1998) 842-845
42. Weltman M.D., Farrell G.C., Hall P., Ingelman-Sundberg M., and Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27 (1998) 128-133
43. Bugianesi E., Manzini P., D'Antico S., Vanni E., Longo F., Leone N., et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39 (2004) 179-187
44. Guillygomarc'h A., Mendler M.H., Moirand R., Jouanolle A.M., David V., and Deugnier Y. HFE mutations in insulin resistance-associated hepatic iron overload. J Hepatol 33 (2000) 515-516
45. Mendler M.H., Turlin B., Moirand R., Jouanolle A.M., Sapey T., Guyader D., et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 117 (1999) 1155-1163
46. Moirand R., Mendler M.H., Guillygomarc'h A., Brissot P., and Deugnier Y. Nonalcoholic steatohepatitis with iron: part of insulin resistance-associated hepatic iron overload?. J Hepatol 33 (2000) 1024-1026
47. Turlin B., Mendler M.H., Moirand R., Guyader D., Guillygomarc'h A., and Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 116 (2001) 263-270
48. Angulo P., Keach J.C., Batts K.P., and Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30 (1999) 1356-1362
49. Bacon B.R., Farahvash M.J., Janney C.G., and Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107 (1994) 1103-1109
50. George D.K., Goldwurm S., MacDonald G.A., Cowley L.L., Walker N.I., Ward P.J., et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114 (1998) 311-318
51. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., and McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
52. Younossi Z.M., Gramlich T., Bacon B.R., Matteoni C.A., Boparai N., O'Neill R., et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 30 (1999) 847-850
53. Bonkovsky H.L., Jawaid Q., Tortorelli K., LeClair P., Cobb J., Lambrecht R.W., et al. Nonalcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis. J Hepatol 31 (1999) 421-429
54. Chitturi S., Weltman M., Farrell G.C., McDonald D., Kench J., Liddle C., et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 36 (2002) 142-149
55. Deguti M.M., Sipahi A.M., Gayotto L.C., Palacios S.A., Bittencourt P.L., Goldberg A.C., et al. Lack of evidence for the pathogenic role of iron and HFE gene mutations in Brazilian patients with nonalcoholic steatohepatitis. Braz J Med Biol Res 36 (2003) 739-745
56. Duseja A., Das R., Nanda M., Das A., Garewal G., and Chawla Y. Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J Gastroenterol 11 (2005) 393-395
57. Yamauchi N., Itoh Y., Tanaka Y., Mizokami M., Minami M., Morita A., et al. Clinical characteristics and prevalence of GB virus C, SEN virus, and HFE gene mutation in Japanese patients with nonalcoholic steatohepatitis. J Gastroenterol 39 (2004) 654-660
58. Facchini F.S., and Saylor K.L. Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann N Y Acad Sci 967 (2002) 342-351
59. Guillygomarc'h A., Mendler M.H., Moirand R., Laine F., Quentin V., David V., et al. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 35 (2001) 344-349
60. Bruix J., Sherman M., Llovet J., Beaugrand M., Lencioni R., Burroughs A., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (2001) 421-430
61. Chapoutot C., Esslimani M., Joomaye Z., Ramos J., Perney P., Laurent C., et al. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut 46 (2000) 711-714
62. Hellerbrand C., Poppl A., Hartmann A., Scholmerich J., and Lock G. HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin Gastroenterol Hepatol 1 (2003) 279-284
63. Fargion S., Stazi M.A., Fracanzani A.L., Mattioli M., Sampietro M., Tavazzi D., et al. Mutations in the HFE gene and their interaction with exogenous risk factors in hepatocellular carcinoma. Blood Cells Mol Dis 27 (2001) 505-511
64. Cauza E., Peck-Radosavljevic M., Ulrich-Pur H., Datz C., Gschwantler M., Schoniger-Hekele M., et al. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol 98 (2003) 442-447
65. Boige V., Castera L., de Roux N., Ganne-Carrie N., Ducot B., Pelletier G., et al. Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. Gut 52 (2003) 1178-1181
66. Nahon P., Sutton A., Rufat P., Ziol M., Thabut G., Schischmanoff P.O., et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 134 (2008) 102-110
67. Sorrentino P., D'Angelo S., Ferbo U., Micheli P., Bracigliano A., and Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on nonalcoholic steatohepatitis. J Hepatol 50 (2009) 351-357
68. Falize L., Guillygomarc'h A., Perrin M., Laine F., Guyader D., Brissot P., et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 44 (2006) 472-477